ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2019
Accuracy of a Novel Histoplasmosis Enzyme Immunoassay to Evaluate Suspicious Lung Nodules.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Evaluation of Lung Cancer Probability Models and Guideline Recommendations in Settings With a High Prevalence of Cancer.CHEST pulmonary · 2026Article
- Misdiagnosis and Coinfection of Localized Pulmonary Histoplasmosis with Pulmonary Tuberculosis: A Systematic Review of Published Cases.Journal of fungi (Basel, Switzerland) · 2026Review
- Practical Guidance for Clinical Microbiology Laboratories: Antibody and antigen detection methods for dimorphic fungal infections.Clinical microbiology reviews · 2025Review
- Improving Lung Cancer Diagnosis with CT Radiomics and Serum Histoplasmosis Testing.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Pulmonary Histoplasmosis: A Clinical Update.Journal of fungi (Basel, Switzerland) · 2023Review
- Development of an Interferon-Gamma Release Assay (IGRA) to Aid Diagnosis of Histoplasmosis.Journal of clinical microbiology · 2022Article
- Improving malignancy risk prediction of indeterminate pulmonary nodules with imaging features and biomarkers.Clinica chimica acta; international journal of clinical chemistry · 2022Article
- The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies.Cancer biomarkers : section A of Disease markers · 2022Article
- Integrated Biomarkers for the Management of Indeterminate Pulmonary Nodules.American journal of respiratory and critical care medicine · 2021Article
- Revising Conventional Wisdom About Histoplasmosis in the United States.Open forum infectious diseases · 2021Review
- Validation of Histoplasmosis Enzyme Immunoassay to Evaluate Suspicious Lung Nodules.The Annals of thoracic surgery · 2021Article
- Enhanced Surveillance for Histoplasmosis-9 States, 2018-2019.Open forum infectious diseases · 2020Article
- Noninvasive biomarkers for lung cancer diagnosis, where do we stand?Journal of thoracic disease · 2020Review
- Histoplasmosis-related Healthcare Use, Diagnosis, and Treatment in a Commercially Insured Population, United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Timely Diagnosis of Histoplasmosis in Non-endemic Countries: A Laboratory Challenge.Frontiers in microbiology · 2020Review
- Advances in Understanding Human Genetic Variations That Influence Innate Immunity to Fungi.Frontiers in cellular and infection microbiology · 2020Review
- Differentiation of non-small cell lung cancer and histoplasmosis pulmonary nodules: insights from radiomics model performance compared with clinician observers.Translational lung cancer research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundGranulomas caused by infectious lung diseases present as indeterminate pulmonary nodules (IPNs) on radiography. Newly available serum enzyme immunoassay (EIA) for histoplasmosis has not been studied for the evaluation of IPNs. We investigated serum biomarkers of histoplasmosis antibodies as an indication of benign disease in IPNs from a highly endemic region.
methodsA total of 152 serum samples from patients presenting with pulmonary nodules ≤30 mm in maximum diameter were analyzed for histoplasmosis antibodies by immunodiffusion and EIA IgG and IgM tests. Serology and FDG-PET/CT scan diagnostic test characteristics were estimated and compared.
resultsCancer prevalence was 55% (
conclusionsA positive EIA test for both IgM and IgG strongly suggested histoplasmosis etiology and benign granuloma for 12% of benign nodules arising from a highly endemic region. Presence of either IgG or IgM histoplasma antibodies was associated with benign disease. The EIA test was more sensitive in assessing histoplasma exposure than immunodiffusion serology. IMPACT: A new CLIA-certified histoplasmosis antibody EIA test measures histoplasmosis exposure, offers a possible alternative clinical diagnosis for benign IPNs, and may improve IPN evaluation while avoiding harmful invasive biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.